Drug Discovery

#Cancer research #Drug development #Drug repositioning #Research

Can common drugs boost immunotherapy cancer treatments?

Widely-used anti-inflammatory drugs make tumours more responsive to treatments which boost the anti-cancer function of the immune system, according to early research by the University of Manchester, funded by Cancer Research UK. The proof-of-concept study on the combination of immunotherapy with anti-inflammatory drugs – used to manage pain and reduce… Read More

#Cancer Research #Editor's Choice #News

#Data #Drug discovery #Drug screening #Screening #Whitepaper

Expertise on analysis of targeted protein degrader compounds

Small molecule drug discovery is expanding beyond traditional strategies focused on identifying compounds that inhibit or block the activity of proteins that cause disease, says Promega. A newer approach to small molecule drug discovery is to selectively target proteins for removal from the cell using degrader compounds, focussing on identifying… Read More

#News

#Covid-19 #Drug delivery #Drug development

EMA issues positive scientific opinion on early treatment of Covid-19

GlaxoSmithKline (GSK) and Vir Biotechnology have announced that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion following the referral of sotrovimab to the CHMP under Article 5(3) of Regulation 726/2004. This relates to the use of sotrovimab for the treatment of… Read More

#Covid-19 #News

#Biotherapeutics #Drug development #Nanomedicine / nanotechnology #Research

New platform uses nanothechnolgy to deliver therapeutics

The Infection Innovation Consortium (iiCON) has launched The Nanotherapeutics Hub, based at the University of Liverpool in the UK, part of Liverpool’s Centre of Excellence for Long-acting Therapeutics (CELT). The agreement will see The Nanotherapeutics Hub work with iiCON to support companies looking to develop nanotherapeutics to combat infectious diseases… Read More

#Editor's Choice #News

Doctor administering a vaccine to patient
#Drug delivery #Drug development #Gene therapy #In vivo

Collaboration expands reach in next generation vaccines

Gamma Biosciences has agreed to make a controlling investment in Mirus Bio for nucleic acid delivery based in Madison, Wisconsin. The transaction will support Mirus’ plans to expand good manufacturing practice (GMP) production and commercialisation of its flagship product TransIT VirusGEN for large scale manufacturing of AAV and LV-based viral… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Drug candidates #Drug design #Drug discovery #Research

AI accelerates discovery of small molecule drug candidates

Exscientia has entered into a collaboration agreement with Bristol-Myers Squibb Company. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology. This expanded collaboration builds upon Exscientia’s existing collaboration with Bristol Myers Squibb that was initiated in… Read More

#News

#Drug development #Drug discovery #Malaria #Research

Malaria stopped in its tracks with new drug compound

Researchers at the Francis Crick Institute and the Latvian Institute of Organic Synthesis have designed a drug-like compound which effectively blocks a critical step in the malaria parasite life cycle and are working to develop this compound into a potential first of its kind malaria treatment. While drugs and mosquito… Read More

#News

#AI #Biobanking #Drug development #Drug discovery #Machine learning #Narrated podcasts

Precision medicine in the era of artificial intelligence

This is the latest episode of the free DDW podcast, “Precision medicine in the era of artificial intelligence”. It covers one narrated article of the same title written for DDW and read aloud by Megan Thomas. It was written by Dr Lofti Chouchane and Dr Javaid Sheikh, who discuss the value… Read More

#Podcasts

#3D modelling #Antibiotics #Biotechnology #Cell / tissue culture #Data #Drug discovery #Drug targets #Drug technology #Imaging

How imaging techniques are innovating drug discovery

Lu Rahman takes look at some of the latest imaging innovation available and how it can benefit drug target identification and drug discovery research. Imaging is an important element within the drug discovery and development process providing researchers with information that can help identify potential drug targets or see how… Read More

#Exclusive Content #News #Trends & Analysis

#Drug development #Drug discovery #ELRIG #Events #Life sciences

Weather the Storm: Drug Discovery and the ELRIG community

On May 27, 2021, ELRIG’s “hot topic” webinar, Weathering the Storm: Drug Discovery & the ELRIG Community takes place virtually. Scientists, medical professionals, business leaders and others associated with the life sciences, which ELRIG consider to be the core of their drug discovery community, and who, throughout the pandemic, have… Read More

#News

#Drug discovery #Gene sequencing #Genome sequencing #Sequencing

Macrogen Europe expands sequencing capacity

Genomic sequencing service provider Macrogen Europe has achieved an upgrade to its next generation sequencing (NGS) capacity. The installation of an additional Illumina NovaSeq 6000 high-throughput sequencing system in its headquarters in the Netherlands helps manage increased demand with high-quality results and fast, reliable turnaround times. The addition of the… Read More

#News

#Biopharmaceuticals #Biotechnology #Drug development #Novel therapeutics

PerkinElmer acquires Nexcelom Bioscience

PerkinElmer has entered into an agreement to acquire Nexcelom Bioscience for US$260 million. The transaction is expected to close during the second quarter of 2021. Nexcelom provides automated cell counting instruments and aids in the development of cell and gene and immuno-oncology therapies, virology drugs and vaccines. Its expected 2021… Read More

#News

#Alzheimer's #Clinical trial #Drug development #Drug discovery #Drug targets #Immuno-oncology

Can this clinical trial move us closer to an Alzheimer’s treatment?

Exscientia has announced a Phase I clinical study of DSP-0038 in the US for the treatment of Alzheimer’s disease psychosis. DSP-0038 is the third molecule created using Exscientia’s Artificial Intelligence (AI) technologies to enter clinical trials. The two earlier compounds are DSP-1181, announced in 2020 together with Sumitomo Dainippon Pharma… Read More

#News

#Antibodies #Awards #Biologics / Biotechnology #Drug development #Oncology #Therapeutics

Matwin spotlights innovation in the fight against cancer

Matwin has picked four companies that will now receive investment from the French oncology accelerator. This was during the MEET2WIN European Oncology Partnering Convention. Step Pharma was awarded ‘First-in-class therapeutic innovation’. The startup’s lead program (STP938) is based on a novel class of oral nucleotide synthesis inhibitors that target CTPS1… Read More

#News